Elhmidi Yacine, Piazza Nicolo, Krane Markus, Deutsch Marcus-André, Mazzitelli Domenico, Lange Rüdiger, Bleiziffer Sabine
Clinic for Cardiovascular Surgery, German Heart Centre, Munich, Germany.
Catheter Cardiovasc Interv. 2014 Aug 1;84(2):283-90. doi: 10.1002/ccd.25366. Epub 2014 Jan 29.
To identify predictors of mortality, functional status, and hemodynamical changes of patients undergoing transcatheter aortic valve implantation (TAVI) for low flow/low gradient aortic stenosis (LF/LG AS).
There is little published data regarding the outcomes of patients with LF/LG AS following TAVI.
Sixty-eight patients with severe AS, left ventricular dysfunction (ejection fraction [EF] <35%) and low flow (LF) AS underwent TAVI. Patients were stratified according to the aortic mean pressure gradient (low gradient [LG]; with Pmean ≤40 mm Hg and high gradient [HG]: Pmean >40 mm Hg). The baseline parameters and clinical outcomes were subsequently compared among the two groups. Cox proportional hazards were used to identify predictors of 6-month mortality.
There were 38 patients in the LG group and 30 patients in the HG group. There were no significant difference in 30-day mortality between the two groups. The 6-month and 1-year mortality, however, was 3.8-fold and 2.8-fold higher in the LG group than in the HG group (37.8% vs. 10.3%, P = 0.01 and 37.8% vs. 13.3%, respectively, P = 0.01). Univariable predictors for 6-month mortality were: STS Score, aortic valve area, and aortic mean pressure gradient. However, only STS Score (HR 1.08, 1.04-1.12, P < 0.001) remained as independent predictor in the multivariable analysis. Six months after TAVI, hemodynamical (EF > 50%) and clinical (NYHA class I) improvements were shown in both HG and LG groups.
LF/LG AS does not influence procedural mortality after TAVI but exhibits a strong impact on 6-month and 1-year mortality. The survivors, however, exhibit considerable hemodynamical and clinical improvements. Therefore, risk stratification and TAVI benefit should be weighted in every patient with LF/LG AS.
确定接受经导管主动脉瓣植入术(TAVI)治疗的低流量/低梯度主动脉瓣狭窄(LF/LG AS)患者的死亡率、功能状态及血流动力学变化的预测因素。
关于TAVI术后LF/LG AS患者的预后,公开数据较少。
68例重度AS、左心室功能不全(射血分数[EF]<35%)及低流量(LF)AS患者接受了TAVI。根据主动脉平均压力梯度将患者分层(低梯度[LG]:平均压力Pmean≤40 mmHg;高梯度[HG]:Pmean>40 mmHg)。随后比较两组的基线参数及临床结局。采用Cox比例风险模型确定6个月死亡率的预测因素。
LG组38例患者,HG组30例患者。两组30天死亡率无显著差异。然而,LG组6个月和1年死亡率分别比HG组高3.8倍和2.8倍(分别为37.8%对10.3%,P = 0.01;37.8%对13.3%,P = 0.01)。6个月死亡率的单变量预测因素为:胸外科医师协会(STS)评分、主动脉瓣面积及主动脉平均压力梯度。但多变量分析中仅STS评分(风险比1.08,1.04 - 1.12,P < 0.001)仍为独立预测因素。TAVI术后6个月,HG组和LG组均出现血流动力学改善(EF>50%)及临床改善(纽约心脏协会[NYHA] I级)。
LF/LG AS不影响TAVI术后的手术死亡率,但对6个月和1年死亡率有强烈影响。然而,存活患者表现出显著的血流动力学及临床改善。因此,对于每例LF/LG AS患者,均应权衡风险分层及TAVI的获益。